- Home
- BYRN vs INBX Comparison
BYRN vs INBX Comparison
Compare BYRN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYRN
- INBX
- Stock Information
- Founded
- BYRN 2005
- INBX 2010
- Country
- BYRN United States
- INBX United States
- Employees
- BYRN N/A
- INBX N/A
- Industry
- BYRN Industrial Machinery/Components
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- BYRN Miscellaneous
- INBX Health Care
- Exchange
- BYRN Nasdaq
- INBX Nasdaq
- Market Cap
- BYRN 485.6M
- INBX 430.2M
- IPO Year
- BYRN N/A
- INBX 2020
- Fundamental
- Price
- BYRN $23.19
- INBX $33.61
- Analyst Decision
- BYRN Strong Buy
- INBX Hold
- Analyst Count
- BYRN 2
- INBX 2
- Target Price
- BYRN $41.50
- INBX N/A
- AVG Volume (30 Days)
- BYRN 490.1K
- INBX 124.8K
- Earning Date
- BYRN 10-09-2025
- INBX 11-13-2025
- Dividend Yield
- BYRN N/A
- INBX N/A
- EPS Growth
- BYRN N/A
- INBX N/A
- EPS
- BYRN 0.62
- INBX N/A
- Revenue
- BYRN $103,528,000.00
- INBX $1,400,000.00
- Revenue This Year
- BYRN $38.94
- INBX $563.00
- Revenue Next Year
- BYRN $21.69
- INBX $230.77
- P/E Ratio
- BYRN $36.61
- INBX N/A
- Revenue Growth
- BYRN 73.56
- INBX N/A
- 52 Week Low
- BYRN $13.10
- INBX $10.81
- 52 Week High
- BYRN $34.78
- INBX $37.53
- Technical
- Relative Strength Index (RSI)
- BYRN 59.64
- INBX N/A
- Support Level
- BYRN $22.32
- INBX N/A
- Resistance Level
- BYRN $24.07
- INBX N/A
- Average True Range (ATR)
- BYRN 1.07
- INBX 0.00
- MACD
- BYRN 0.22
- INBX 0.00
- Stochastic Oscillator
- BYRN 73.77
- INBX 0.00
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.